BioCentury | Feb 1, 2016


A year after unveiling its Pentarin platform, Tarveda Therapeutics Inc. and its investors have seen enough data to exclusively focus the cancer company on its biologic-drug conjugates. Tarveda (formerly Blend Therapeutics Inc. ) last week raised...
BC Extra | Jan 28, 2016
Financial News

Tarveda raises $38M series C

Tarveda Therapeutics Inc. (Watertown, Mass.) raised $38 million in a series C round led by new investor Novo A/S (Hellerup, Denmark) and founding investor New Enterprise Associates. Existing investors Flagship Ventures, NanoDimension and Eminent Venture...
BioCentury | Jan 26, 2015
Emerging Company Profile

Cloaking conjugates

After spending its first 18 months using medicinal chemistry to discover novel platinum-based cytotoxic agents for cancer, Blend Therapeutics Inc. has decided to branch out into developing a biologic-drug conjugate platform that may provide greater...
BioCentury | Jan 12, 2015

Blend(ing) a platform

A fresh capital infusion has provided Blend Therapeutics Inc. the opportunity to develop a platform to optimize the delivery of its cytotoxic agents to cancer cells - a challenge identified by investors as the main issue...
Items per page:
1 - 4 of 4